MedTrace Logo

Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours

NCT03262207 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2017-08-25

No results posted yet for this study

Summary

Recent data suggest that sperm cells carry an epigenetic message during spermatogenesis and that this message is crucial for the future development of the embryo. This epigenetic signature is notably represented by methylation of genes subjected to imprinting (GSI) and the methylation of transposable elements (TE). Data on the maintenance of the imprint and of the control of TE accompanying human gametogenesis in a context of adult germinal testicular cancers, seminomas, are extremely fragmentary for tumour tissues and inexistent for gametes.

The aim of this study is to determine whether patients with seminomas in comparison with fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes.

This study is based on the use of an existing collection of biological samples. 90 samples will be selected and split into 3 groups:

* Group 1: 30 sperm samples from patients with seminomatous testicular tumours
* Group 2: 30 sperm samples from fertile patients
* Group 3: 30 sperm samples from infertile patients

After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they will be analysed.

Conditions

  • Seminomas

Interventions

OTHER

Extraction genomic DNA

OTHER

Analysis of methylation profiles of numerous GSI and TE

OTHER

Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)

OTHER

Method of protein detection by immunostaining and flow cytometry

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262207 on ClinicalTrials.gov